TheTechno Optimist.

Sasineprocel (ANPD001)Aspen Neuroscience—Aspen reports 12-month ASPIRO data: patient-derived dopamine cells improve Parkinson's symptoms without immunosuppressionSasineprocel (ANPD001)Aspen Neuroscience—Aspen completes ASPIRO dosing with a frozen, ready-to-inject cell product ahead of phase 3

Aspen Neuroscience

Personalised stem-cell neurons, Parkinson's

USprivateaspenneuroscience.com (opens aspenneuroscience.com)Checked 11 Oct

The brief

Analyst view
  • Sasineprocel (ANPD001): 15 patients dosed in the ASPIRO phase 1/2a by June 2026.
  • 12-month data: about 2 more hours a day of good symptom control, without immunosuppression.
  • San Diego GMP plant built for pivotal-trial manufacturing; preparing a phase 3 package.
Primer